Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells

Atherosclerosis. 2012 Apr;221(2):366-74. doi: 10.1016/j.atherosclerosis.2011.12.034. Epub 2011 Dec 29.

Abstract

Objective: To investigate mechanisms of lymphangiogenesis in aortic valve stenosis (AS).

Methods: Lymphatic vessels were visualized with LYVE-1 staining in 20 control, 5 sclerotic, and 40 stenotic human aortic valves. Vascular endothelial growth factors (VEGFs) VEGF-C and VEGF-D, and their lymphangiogenic receptor VEGFR-3, and the angiogenic VEGFR-2 were analysed by quantitative real-time PCR and immunohistochemistry. Cultured myofibroblasts derived from human stenotic aortic valves, and cultured human mast cells were used to study VEGF-C regulation, and VEGF-C and VEGF-A were quantified from cell culture media by enzyme immunoassays.

Results: Lymphatic vessels, VEGF-C, VEGF-D, VEGFR-3 and VEGFR-2 all were present in the aortic valves. In AS, the number of lymphatic vessels and the expression of VEGF-D, VEGFR-3, and VEGFR-2 were increased. Moreover, the numbers of lymphatic vessels correlated positively with those of neovessels (r = 0.525, p = 0.001) and mast cells (r = 0.374, p = 0.017). Cultured valvular myofibroblasts produced VEGF-C, and addition of tumour necrosis factor alpha (TNF-α) to the cells augmented its secretion. In contrast, proteases released by activated human mast cells degraded VEGF-C.

Conclusion: These results show that lymphangiogenesis is induced in advancing AS. Furthermore, valvular myofibroblasts and activated mast cells were identified as novel regulators of lymphangiogenesis in aortic valves.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aortic Valve / metabolism*
  • Aortic Valve / pathology
  • Aortic Valve / physiopathology
  • Aortic Valve Stenosis / metabolism*
  • Aortic Valve Stenosis / pathology
  • Aortic Valve Stenosis / physiopathology
  • Case-Control Studies
  • Cells, Cultured
  • Fluorescent Antibody Technique
  • Humans
  • Immunoenzyme Techniques
  • Immunohistochemistry
  • Lymphangiogenesis*
  • Lymphatic Vessels / metabolism*
  • Lymphatic Vessels / pathology
  • Lymphatic Vessels / physiopathology
  • Mast Cells / metabolism*
  • Mast Cells / pathology
  • Myofibroblasts / metabolism*
  • Myofibroblasts / pathology
  • Peptide Hydrolases / metabolism
  • RNA, Messenger / metabolism
  • Real-Time Polymerase Chain Reaction
  • Signal Transduction
  • Time Factors
  • Tumor Necrosis Factor-alpha / metabolism
  • Vascular Endothelial Growth Factor C / genetics
  • Vascular Endothelial Growth Factor C / metabolism
  • Vascular Endothelial Growth Factor D / genetics
  • Vascular Endothelial Growth Factor D / metabolism
  • Vascular Endothelial Growth Factor Receptor-2 / genetics
  • Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • Vascular Endothelial Growth Factor Receptor-3 / genetics
  • Vascular Endothelial Growth Factor Receptor-3 / metabolism
  • Vesicular Transport Proteins / metabolism

Substances

  • LYVE1 protein, human
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • VEGFC protein, human
  • Vascular Endothelial Growth Factor C
  • Vascular Endothelial Growth Factor D
  • Vesicular Transport Proteins
  • Vascular Endothelial Growth Factor Receptor-2
  • Vascular Endothelial Growth Factor Receptor-3
  • Peptide Hydrolases